KN-026
As of the edition of 20 October 2026, KN-026 is a drug: in active development; acts on ERBB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Unknown
- Registered trials
- 14, 1 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | P04626 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 7 | 1 | 4 | 0 |
| Phase 3 | 3 | 0 | 3 | 0 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu Alphamab Biopharmaceuticals | Lead sponsor of trials | 2018 to now |
| Shanghai JMT-Bio | Lead sponsor of trials | 2024 to now |
| Cspc | Lead sponsor of trials | 2026 to now |